Please ensure Javascript is enabled for purposes of website accessibility

7 Big Pharma Stocks Near 52-Week Lows

By Anand Chokkavelu, CFA – Updated Apr 6, 2017 at 10:54AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Trolling the bottom for upside potential.

If you're aiming to "buy low and sell high," then it makes infinite sense to start your search with bargain-priced stocks. Regularly reviewing a list of stocks trading near their 52-week lows can be a great first step.

Here, I'll try to do the initial legwork for you. To prevent us from being inundated with scores of disparate companies, I'll conduct my search by industry. This will allow us to make some initial comparisons among semi-related companies.

There are 24 industry groups as defined by the Global Industry Classification Standard (GICS). The pharmaceuticals industry is one of them.

Below are the top seven companies in this space (by market cap) that are hugging 52-week lows.

Company

Market Capitalization
(in Millions)

Change From 52-Week Low

P/E Ratio (Trailing)

Johnson & Johnson (NYSE: JNJ)

$175,899

12.3%

13.1

Novartis (NYSE: NVS)

$136,648

13.8%

12.4

GlaxoSmithKline (NYSE: GSK)

$107,630

19.9%

16.5

sanofi-aventis (NYSE: SNY)

$91,805

14.5%

10.9

Amgen (Nasdaq: AMGN)

$55,553

15.3%

12.0

Teva Pharmaceutical (Nasdaq: TEVA)

$48,730

15.5%

19.4

Eli Lilly (NYSE: LLY)

$43,889

18.9%

9.34


Source: Capital IQ, a division of Standard & Poor's. Data as of Oct. 18, 2010.

There are certainly some big names trading near their lows. As I warn frequently in this series, though, be careful, because many of these stocks are also trading in a tight band -- hence they're close to their highs as well.

So let's focus on valuation instead. On a P/E ratio basis, each is trading at cheap to moderate levels. And I see that each of their price-to-free cash flow ratios is roughly in line with their P/E ratios. That's a good sign.

I've written about Johnson & Johnson recently as an interesting play. Ideally, I'd like a buy-in price below $60 a share. It trades a little above that now.

As you research any of these stocks further, remember that the fear for Big Pharma is about the fading prospects for their drug pipelines. Any investment thesis should consider how effective they'll be at replenishing their blockbuster drugs once they're off patent.   

Interested in reading more about these stocks? Add them to My Watchlist to find all of our Foolish analysis on them.

Anand Chokkavelu doesn't own shares of any companies mentioned. He posts his favorite articles on his Twitter feed.

GlaxoSmithKline and Novartis are Motley Fool Global Gains recommendations. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, which is a Motley Fool Income Investor selection. The Fool owns shares of GlaxoSmithKline, Johnson & Johnson, and Teva Pharmaceutical Industries.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$311.46 (0.19%) $0.59
Sanofi Stock Quote
Sanofi
SNY
$38.40 (-1.87%) $0.73
Novartis AG Stock Quote
Novartis AG
NVS
$76.01 (-1.47%) $-1.13
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$226.97 (-0.34%) $0.78
GSK Stock Quote
GSK
GSK
$29.36 (-2.17%) $0.65
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.90 (-1.98%) $0.16
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$166.72 (0.33%) $0.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.